EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , 

 ISSN 2394-3211

Impact Factor: 6.222

 ICV - 79.57

Abstract

SGLT2 INHIBITORS: PROMISING NEW DRUGS FOR TYPE 2 DIABETES MELLITUS

Dr. Abhijeet Bhagat, Dr. Deepak Bhosle, Dr. Asif Sayyed*, Dr. Vasundhara Bhople, Dr. Ayman Ali Khan, Dr. Zubair Quazi

ABSTRACT

Due to change in life style there is a growing pandemic of Type 2 diabetes mellitus. Currently it affects more than 3 million people worldwide and this number is expected to grow to more than 5 million by the year 2030. Sodium glucose transporter 2 (SGLT2) is a new class of antidiabetic drugs which unlike many other antidiabetic drugs acts by insulin dependent mechanism and hence less prone to cause clinically significant hypoglycemia. Canagliflozin is the prototype drug of this group. It was first approved by food and drug administration in 2013. Other SGLT2 inhibitors approved by FDA for type II diabetes mellitus are dapagliflozin, and empagliflozin. The mechanism of action of these drugs is by inhibition of SGLT2 which is a low- affinity, high capacity glucose transporter which is located in the proximal tubule in the kidneys. This co-transporter is responsible for majority of the glucose reab-sorption from proximal tubule. Inhibition of SGLT2 leads to increase in glucose excretion from proximal tubules of kidney. This increase in excretion consequently cause reduction in blood glucose levels. In addition to increased excretion SGLT2 inhibitors also act by increasing insulin sensitivity and increase glucose uptake in muscle cells. It further decrease gluconeogenesis. The advantages of SGLT2 include weight reduction, low incidence of hypogly-cemic episodes and reduction in blood pressure levels. While it is usually well tolerated it may increase the propen-sity to develop urinary tract infections by virtue of increasing glucose excretion. Another major side effect associ-ated with the use of this class of drugs is lactic acidosis. Taking into consideration pros and cons SGLT2 inhibitors appears to be a promising new treatment for patients of Type II diabetes mellitus in whom first and second line drugs are not working or are contraindicated for some reason.

Keywords: Type 2 diabetes mellitus, SGLT2 inhibitors, Lactic acidosis, Urinary tract Infections.


[Full Text Article]

INDEXING

NEWS & UPDATION

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 August 2020 Issue has been Published, Kindly check it on http://www.ejpmr.com/home/current_issues

  • EJPMR AUGUST ISSUE PUBLISHED

    AUGUST 2020 Issue has been successfully launched on 1 August 2020.

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from  5.804 to 6.222, due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing